Merck KGaA (FRA:MRK) has been assigned a €103.00 ($119.77) price target by equities research analysts at Warburg Research in a report released on Friday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Warburg Research’s price objective suggests a potential upside of 12.27% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. DZ Bank reiterated a “neutral” rating on shares of Merck KGaA in a research note on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Monday, April 15th. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the company a “sell” rating in a research note on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Monday, May 13th. Finally, UBS Group set a €104.00 ($120.93) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Monday, May 13th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of €100.53 ($116.89).
MRK stock opened at €91.74 ($106.67) on Friday. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: What are no-load funds?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.